Clinical Trial Update: A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, and pharmacokinetics of HC-ER in patients with osteoarthritis pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• HC-ER

Snippet

Sponsor: Zogenix, Inc. | Conditions: Osteoarthrosis | Phase 2 | Status: COMPLETED